NCT03082209 2022-12-09A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic MalignanciesAbbViePhase 1 Completed153 enrolled
NCT02431260 2019-06-14An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced MalignanciesIncyte CorporationPhase 1/2 Terminated69 enrolled 34 charts